AR024462A1 - Tabletas farmaceuticas - Google Patents

Tabletas farmaceuticas

Info

Publication number
AR024462A1
AR024462A1 ARP000103154A ARP000103154A AR024462A1 AR 024462 A1 AR024462 A1 AR 024462A1 AR P000103154 A ARP000103154 A AR P000103154A AR P000103154 A ARP000103154 A AR P000103154A AR 024462 A1 AR024462 A1 AR 024462A1
Authority
AR
Argentina
Prior art keywords
tablets
pharmaceutical tablets
refers
pharmaceutical
bisphosphonates
Prior art date
Application number
ARP000103154A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR024462A1 publication Critical patent/AR024462A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a tabletas farmacéuticas, utiles para administrar ingredientes activos farmacéuticos, tales como bisfosfonatos. Estas tabletas hanmejorado las propiedades superficiales que pueden ayudar al tránsito esofageal, reduciendo así elpotencial de los efectos gastrointestinales adversos. Lapresente también se refiere a procesos para preparar dichas tabletas farmacéuticas nuevas.
ARP000103154A 1999-07-01 2000-06-23 Tabletas farmaceuticas AR024462A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14198799P 1999-07-01 1999-07-01

Publications (1)

Publication Number Publication Date
AR024462A1 true AR024462A1 (es) 2002-10-02

Family

ID=22498098

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103154A AR024462A1 (es) 1999-07-01 2000-06-23 Tabletas farmaceuticas

Country Status (11)

Country Link
US (2) US20010036475A1 (es)
EP (1) EP1196175A1 (es)
JP (1) JP2003503460A (es)
KR (1) KR20020015063A (es)
AR (1) AR024462A1 (es)
AU (1) AU6055400A (es)
CA (1) CA2378521A1 (es)
HK (1) HK1041816A1 (es)
IL (1) IL146632A0 (es)
NZ (1) NZ515614A (es)
WO (1) WO2001001991A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
EP2172192A1 (en) 2001-12-24 2010-04-07 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder of granular material, and process and tooling for producing it
KR20140021045A (ko) 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
JP4427453B2 (ja) 2002-12-20 2010-03-10 エフ．ホフマン−ラ ロシュ アーゲー 高用量イバンドロネート製剤
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9711456B2 (en) 2015-12-19 2017-07-18 International Business Machines Corporation Composite manganese nitride/low-K dielectric cap
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. ORAL TESTOSTERONE UNDECANOATE THERAPY
EP3918007A1 (de) * 2019-01-28 2021-12-08 Katjes Fassin GmbH. + Co. Kommanditgesellschaft Apfelwachs-beinhaltende zusammensetzungen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1036368A (en) 1963-10-31 1966-07-20 Nat Dairy Prod Corp Method for the manufacture of lactose-containing tablets
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JPH07100665B2 (ja) 1987-12-23 1995-11-01 信越化学工業株式会社 被覆薬剤の製造方法
CA1339805C (en) 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JP2525478B2 (ja) 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
AU744156B2 (en) * 1996-10-28 2002-02-14 General Mills Inc. Embedding and encapsulation of controlled release particles
SK284690B6 (sk) 1997-06-11 2005-09-08 The Procter And Gamble Company Ústna dávkovacia forma na zvýšenie ochrany horného tráviaceho traktu
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제

Also Published As

Publication number Publication date
CA2378521A1 (en) 2001-01-11
US6623755B2 (en) 2003-09-23
KR20020015063A (ko) 2002-02-27
WO2001001991A1 (en) 2001-01-11
US20010036475A1 (en) 2001-11-01
EP1196175A1 (en) 2002-04-17
AU6055400A (en) 2001-01-22
IL146632A0 (en) 2002-07-25
JP2003503460A (ja) 2003-01-28
US20020187186A1 (en) 2002-12-12
HK1041816A1 (zh) 2002-07-26
NZ515614A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
AR024462A1 (es) Tabletas farmaceuticas
GT199900203A (es) Composiciones de celecoxib.
BRPI0509184A (pt) composições farmacêuticas
AR023401A1 (es) Derivados de 1,4-benzotiazepina-1,1-dioxido sustituidos con restos de azucar, procedimientos para su preparacion, medicamentos que contienen estoscompuestos, y su empleo para preparar un medicamento
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
DOP2000000109A (es) Derivados de tiazolilamida
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
BR0207726A (pt) Sais farmacêuticos
ES2065701T3 (es) Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas.
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
HK1076605A1 (en) Formulations
DE60205870D1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
CO6362017A2 (es) Peptidos antivirales terapeuticos
BRPI0620229B8 (pt) formulações farmaceuticas e processos de produção da ditas formulações
CO5390076A1 (es) Composiciones farmaceuticas
ECSP088635A (es) Formulaciones orales que comprenden tigeciclina
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
EA201490544A1 (ru) Препараты и лекарственные формы на основе окисленных фосфолипидов
AR026338A1 (es) Dihidrotiazoles policiclicos, provistos en posicion 2 de radicales alquilo sustituidos, procedimiento para su preparacion y su utilizacion comomedicamentos
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
NO20064783L (no) Opplosningstabeletter med licarbazepin
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax

Legal Events

Date Code Title Description
FA Abandonment or withdrawal